Inactive Instrument

HemaCare Corporation Share Price OTC Bulletin Board

Equities

Healthcare Facilities & Services

Sales 2017 20.21M 1.61B Sales 2018 28.51M 2.28B Capitalization 125M 9.97B
Net income 2017 4M 320M Net income 2018 4M 320M EV / Sales 2017 1.29 x
Net cash position 2017 9.06M 724M Net cash position 2018 9.9M 791M EV / Sales 2018 4.03 x
P/E ratio 2017
8.18 x
P/E ratio 2018
27.6 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 94.17%
More Fundamentals * Assessed data
Dynamic Chart
HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio CI
MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials CI
Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation. CI
Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million. CI
HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate CI
HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China CI
Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019 CI
HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018 CI
HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP CI
HemaCare Corporation Moves its Global Headquarters to Northridge, California CI
HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies CI
HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018 CI
HemaCare Corporation Announces Executive Appointments CI
HemaCare Corporation Reports Earnings Results for the Full Year Ended December 31, 2017 CI
HemaCare Corporation and Charles River Laboratories International Inc. Announces Strategic Partnership to Accelerate Drug Discovery and Development CI
More news
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 58 -
Chief Operating Officer - 31/12/02
Members of the board TitleAgeSince
Chief Executive Officer - -
More insiders
Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.
More about the company